Acknowledgments The authors would like to extend their acknowledgement to Dr Dermot Ryan for his clinical and scientific input. Funding: This study was partly funded by Roche Products Ltd and the Observational and Pragmatic Research Institute (OPRI). Roche was not involved in the preparation, drafting or editing of this manuscript. Data availability statement: The data set supporting the conclusions of this article was derived from the Optimum Patient Care Research Database (www.opcrd.co.uk). The authors do not have permission to give public access to the study data set; researchers may request access to OPCRD data for their own purposes. Access to OPCRD can be made via the OPCRD website (https://opcrd.co.uk/our-database/data-requests/) or ...
International audienceBACKGROUND:Since 2009, IPF patients across Europe are recruited into the eurIP...
Background: FIBRONET was an observational, multicentre, prospective cohort study investigating the b...
International audienceBACKGROUND: There is a paucity of data on the epidemiology, survival estimates...
OBJECTIVE: To explore the clinical pathways, including signs and symptoms, and symptom progression p...
Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing...
Background: The early diagnosis of idiopathic pulmonary fibrosis (IPF) has become increasingly impor...
Background: The FinnishIPF registry is a prospective, longitudinal national registry study on the ep...
Background/Objectives: This study will aim to characterise disease behaviour during the peri-diagnos...
Idiopathic pulmonary fibrosis (IPF) is a fatal condition with limited treatment options. The diagnos...
Rationale: The level of diagnostic likelihood at which physicians prescribe antifibrotic therapy wit...
This study will aim to characterise disease behaviour during the peri-diagnostic period in patients ...
BACKGROUND Idiopathic pulmonary fibrosis (IPF) differs substantially from other idiopathic inters...
Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) ...
Introduction: The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS) is a multicentre, pros...
Aim of the study: Potential care implications of antifibrotic reimbursement restrictions werestudied...
International audienceBACKGROUND:Since 2009, IPF patients across Europe are recruited into the eurIP...
Background: FIBRONET was an observational, multicentre, prospective cohort study investigating the b...
International audienceBACKGROUND: There is a paucity of data on the epidemiology, survival estimates...
OBJECTIVE: To explore the clinical pathways, including signs and symptoms, and symptom progression p...
Background: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing...
Background: The early diagnosis of idiopathic pulmonary fibrosis (IPF) has become increasingly impor...
Background: The FinnishIPF registry is a prospective, longitudinal national registry study on the ep...
Background/Objectives: This study will aim to characterise disease behaviour during the peri-diagnos...
Idiopathic pulmonary fibrosis (IPF) is a fatal condition with limited treatment options. The diagnos...
Rationale: The level of diagnostic likelihood at which physicians prescribe antifibrotic therapy wit...
This study will aim to characterise disease behaviour during the peri-diagnostic period in patients ...
BACKGROUND Idiopathic pulmonary fibrosis (IPF) differs substantially from other idiopathic inters...
Over the past decade, several large registries of patients with idiopathic pulmonary fibrosis (IPF) ...
Introduction: The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS) is a multicentre, pros...
Aim of the study: Potential care implications of antifibrotic reimbursement restrictions werestudied...
International audienceBACKGROUND:Since 2009, IPF patients across Europe are recruited into the eurIP...
Background: FIBRONET was an observational, multicentre, prospective cohort study investigating the b...
International audienceBACKGROUND: There is a paucity of data on the epidemiology, survival estimates...